Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Myriad Genetics (MYGN) Tax Provisions (2016 - 2025)

Myriad Genetics has reported Tax Provisions over the past 17 years, most recently at -$1.0 million for Q4 2025.

  • Quarterly Tax Provisions fell 129.41% to -$1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$29.2 million through Dec 2025, down 848.72% year-over-year, with the annual reading at -$29.2 million for FY2025, 868.42% down from the prior year.
  • Tax Provisions was -$1.0 million for Q4 2025 at Myriad Genetics, down from $1.2 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $15.2 million in Q3 2021 and troughed at -$35.9 million in Q4 2021.
  • The 5-year median for Tax Provisions is -$500000.0 (2024), against an average of -$4.4 million.
  • Year-over-year, Tax Provisions skyrocketed 800.0% in 2024 and then tumbled 29400.0% in 2025.
  • A 5-year view of Tax Provisions shows it stood at -$35.9 million in 2021, then surged by 72.7% to -$9.8 million in 2022, then skyrocketed by 88.78% to -$1.1 million in 2023, then soared by 409.09% to $3.4 million in 2024, then plummeted by 129.41% to -$1.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Tax Provisions are -$1.0 million (Q4 2025), $1.2 million (Q3 2025), and -$100000.0 (Q2 2025).